Avanos Medical - AVNS Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price objectives for Avanos Medical's shares. Their AVNS share price forecasts range from $26.00 to $34.00. On average, they anticipate the company's stock price to reach $29.33 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts.

Avanos Medical's stock was trading at $27.06 at the beginning of 2023. Since then, AVNS stock has increased by 11.0% and is now trading at $30.04.
View the best growth stocks for 2023 here.

Avanos Medical saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 863,600 shares, an increase of 19.2% from the December 15th total of 724,600 shares. Based on an average daily trading volume, of 224,100 shares, the short-interest ratio is currently 3.9 days. Currently, 1.9% of the shares of the company are short sold.
View Avanos Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AVNS earnings forecast.

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings data on Wednesday, November, 2nd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.03. The firm had revenue of $202 million for the quarter, compared to analyst estimates of $205.47 million. Avanos Medical had a trailing twelve-month return on equity of 5.74% and a net margin of 5.39%. The business's revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.25 earnings per share.

Avanos Medical updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $1.45-$1.65 for the period, compared to the consensus earnings per share estimate of $1.51. The company issued revenue guidance of $815.00 million-$835.00 million, compared to the consensus revenue estimate of $824.62 million.

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.12%), Exchange Traded Concepts LLC (0.08%), Ziegler Capital Management LLC (0.07%), Yousif Capital Management LLC (0.06%), Fulton Bank N.A. (0.02%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $30.04.

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.40 billion and generates $744.60 million in revenue each year. The company earns $5.20 million in net income (profit) each year or $0.90 on an earnings per share basis.

The company employs 4,555 workers across the globe.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.